Please login to the form below

Not currently logged in
Email:
Password:

10 Years of EU Orphan Drug Regulation

The European Medicines Agency is marking the 10th anniversary of orphan drug regulation implementation in Europe with a conference and workshops

It is 10 years since orphan drug regulation was implemented in Europe and the European Medicines Agency (EMA) is marking the anniversary with various conferences and workshops during April and May.

In April 2000, Regulation (EC) No 141/2000 of the European Parliament and the Council on Orphan Medicinal Products came into effect. Since then, over 700 products have received orphan designation to treat rare disorders.

The regulation established the criteria for orphan designation in the EU and delineated the incentives, including market exclusivity, protocol assistance, and access to the centralised procedure for marketing authorisation. The regulation was also developed to encourage the research, development and marketing of medicines to treat, diagnose or prevent rare diseases.    

Two workshops and a conference are scheduled to take place at EMA headquarters in London. The first workshop, on nanomedicines, is scheduled for April 26-27, and the second, on May 10, will focus on stem cell-based therapies. 

Then on May 3-4 there will be a conference, entitled 10 Years of the Orphan Regulation in Europe, featuring plenary sessions, discussions and three parallel workshops on the development of products for rare diseases, research for rare diseases and patients' views on the Regulation. 

Further details are available from the EMA

24th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics